IMA

ImageneBio Inc NASDAQ

Healthcare ·Biotechnology ·US · inmagenebio.com

$5.71

After hrs $5.82 -0.17%

Mkt Cap $63.9M

52w Low $3.94 12.6% of range 52w High $18.00

50d MA $5.77 200d MA $8.31

P/E (TTM) -0.5x

EV/EBITDA -0.2x

P/B 0.2x

Debt/Equity 0.1x

ROE -34.1%

P/FCF -0.7x

RSI (14) —

ATR (14) —

Beta 0.55

50d MA $5.77

200d MA $8.31

Avg Volume 354.4K

About

Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Mar 10, 2026	AMC	-1.45	-0.62	+57.2%	6.07	+3.1%	-1.0%	-1.2%	-2.6%	+2.1%	-0.8%	—
Nov 12, 2025	AMC	-1.47	-2.91	-98.0%	8.55	-0.2%	-2.6%	-4.6%	-9.9%	-10.8%	-14.3%	—
Jul 24, 2025	AMC	-0.14	-0.06	+57.1%	16.44	-91.6%	+4.4%	-0.4%	-7.5%	-7.0%	+8.9%	—
May 8, 2025	AMC	-0.21	-0.18	+14.3%	12.96	+0.0%	+4.6%	+5.6%	+7.4%	+0.0%	+1.9%	—
Mar 6, 2025	AMC	-0.19	-0.18	+5.3%	17.16	-0.7%	+0.7%	-1.4%	-3.5%	-2.8%	-4.9%	—
Nov 7, 2024	AMC	-0.27	-0.19	+29.6%	20.28	+0.0%	+4.1%	+3.6%	+4.1%	+3.0%	+1.2%	—
Aug 8, 2024	AMC	-0.31	-0.27	+12.9%	19.56	+0.0%	+0.0%	+0.6%	+3.1%	+2.5%	+3.1%	—
May 13, 2024	AMC	-0.40	-0.28	+30.0%	15.84	+2.3%	+0.8%	+1.5%	+6.1%	+8.3%	+6.1%	—
Mar 12, 2024	AMC	-0.41	-0.41	+0.0%	16.68	+0.7%	+1.4%	+5.0%	+12.9%	+7.9%	+7.9%	—
Nov 9, 2023	AMC	-0.44	-0.40	+9.1%	15.96	-1.5%	+9.8%	+11.3%	+2.3%	+5.3%	+12.0%	—
Aug 10, 2023	AMC	-0.48	-0.44	+8.3%	54.48	+1.1%	-5.3%	-4.4%	-7.0%	-6.6%	-8.6%	—
May 15, 2023	AMC	-0.46	-0.39	+15.2%	84.00	-1.9%	-12.0%	-7.4%	-11.9%	-9.3%	-13.0%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Jul 25	Wedbush	Maintains	Neutral → Neutral	—	$16.44	$1.38	-91.6%	+4.4%	-0.4%	-7.5%	-7.0%	+8.9%
Nov 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$21.12	$21.00	-0.6%	-0.6%	+0.0%	-1.1%	-2.8%	-4.0%
Aug 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.56	$19.68	+0.6%	+0.6%	+3.1%	+2.5%	+3.1%	+4.9%
May 29	Wedbush	Downgrade	Outperform → Neutral	—	$15.96	$18.72	+17.3%	+25.6%	+34.6%	+33.1%	+33.8%	+30.8%
May 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.96	$18.72	+17.3%	+25.6%	+34.6%	+33.1%	+33.8%	+30.8%
May 14	Wedbush	Maintains	Outperform → Outperform	—	$15.84	$16.20	+2.3%	+0.8%	+1.5%	+6.1%	+8.3%	+6.1%
Mar 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$18.00	$18.36	+2.0%	+0.0%	+4.0%	+0.0%	-1.3%	-4.0%
Mar 12	HC Wainwright & Co.	Maintains	Buy → Buy	—	$17.52	$17.28	-1.4%	-4.8%	-3.4%	+0.0%	+7.5%	+2.7%
Jan 19	Wedbush	Maintains	Outperform → Outperform	—	$19.68	$20.40	+3.7%	-7.3%	-4.3%	-14.6%	-14.6%	-21.3%
Jan 19	HC Wainwright & Co.	Maintains	Buy → Buy	—	$19.68	$20.40	+3.7%	-7.3%	-4.3%	-14.6%	-14.6%	-21.3%
Nov 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$49.56	$47.04	-5.1%	-67.8%	-64.6%	-64.2%	-67.1%	-66.1%
Aug 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$50.40	$50.04	-0.7%	+8.1%	+2.4%	+3.3%	+0.5%	+1.0%
Aug 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$59.16	$59.52	+0.6%	-7.5%	-11.4%	-14.8%	-7.9%	-12.8%
May 24	HC Wainwright & Co.	Maintains	Buy → Buy	—	$69.72	$69.24	-0.7%	+3.3%	+6.5%	+2.8%	-0.2%	+11.0%
May 16	Credit Suisse	Maintains	Outperform → Outperform	—	$84.00	$82.44	-1.9%	-12.0%	-7.4%	-11.9%	-9.3%	-13.0%
Mar 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$51.60	$49.81	-3.5%	-4.4%	-14.0%	-2.3%	-12.3%	-14.4%
Mar 15	Credit Suisse	Maintains	Outperform → Outperform	—	$50.52	$48.60	-3.8%	+1.0%	+2.1%	-2.4%	-12.1%	-0.2%
Nov 29	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.04	$30.00	+3.3%	+0.4%	-7.9%	+3.3%	-2.5%	-7.9%
Nov 29	Credit Suisse	Maintains	Outperform → Outperform	—	$29.04	$30.00	+3.3%	+0.4%	-7.9%	+3.3%	-2.5%	-7.9%
Nov 8	Credit Suisse	Maintains	Outperform → Outperform	—	$27.60	$31.20	+13.0%	+0.0%	-4.3%	-7.8%	-7.8%	-3.9%
May 13	Credit Suisse	Maintains	Outperform → Outperform	—	$44.88	$46.92	+4.5%	+0.0%	-2.4%	+7.2%	-0.5%	-1.1%
Apr 13	HC Wainwright & Co.	Maintains	Buy → Buy	—	$81.60	$91.44	+12.1%	+7.4%	+2.8%	+0.0%	-4.9%	-8.7%
Dec 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$180.48	$187.68	+4.0%	-1.3%	-5.1%	-11.2%	-7.7%	-12.2%
Aug 13	Credit Suisse	Maintains	Outperform → Outperform	—	$132.36	$133.92	+1.2%	-2.3%	-0.1%	+3.4%	+3.3%	-0.7%
Apr 20	Jefferies	Maintains	Buy → Buy	—	$239.28	$239.28	+0.0%	-7.8%	-3.5%	+0.5%	+5.0%	+10.4%
Apr 20	Credit Suisse	Maintains	Outperform → Outperform	—	$239.28	$239.28	+0.0%	-7.8%	-3.5%	+0.5%	+5.0%	+10.4%
Apr 20	William Blair	Maintains	Outperform → Outperform	—	$239.28	$239.28	+0.0%	-7.8%	-3.5%	+0.5%	+5.0%	+10.4%

Recent Filings

8-K · 1.01 ! Medium

Unknown — 8-K 1.01: Equity Issuance

IMA issued equity with a 19.99% ownership cap, likely a strategic investment that limits any single party's control while raising capital without triggering excessive dilution concerns for existing shareholders.

Apr 13

8-K

Unknown — 8-K Filing

A new executive with financial and operational leadership experience from biotech has joined Immunomedics, signaling potential management strengthening for operational efficiency and financial discipline.

Mar 17

8-K

Unknown — 8-K Filing

ImageneBio's full-year 2025 results filing suggests potential clinical progress or operational updates that likely triggered mandatory disclosure, making this critical for evaluating the biotech's pipeline advancement and cash runway before next funding needs.

Mar 10

8-K

ImageneBio, Inc. -- 8-K Filing

ImageneBio's 8-K filing confirms its SEC reporting status, though specific material events or corporate developments are not clearly detailed in this technical documentation reference.

Feb 17

Data updated apr 25, 2026 3:14pm · Source: massive.com